Many studies have investigated the potential prognostic and predictive role of PD-L1 in prostatic carcinoma (PC). We performed a systematic literature review (PRISMA guidelines) to critically evaluate human tissue-based studies (immunohistochemistry, molecular analysis, etc.), experimental research (cell lines, mouse models), and clinical trials. Despite some controversial results and study limitations, PD-L1 expression by tumor cells may be related to clinic–pathologic features of adverse outcome, including advanced tumor stage (high pT, presence of lymph node, and distant metastases), positivity of surgical margins, high Grade Group, and castration resistance. Different PD-L1 positivity rates may be observed in matched primary PCs and various metastatic sites of the same patients. Over-fixation, type/duration of decalcification, and PD-L1 antibody clone may influence the immunohistochemical analysis of PD-L1 on bone metastases. PD-L1 seemed expressed more frequently by castration-resistant PCs (49%) as compared to hormone-sensitive PCs (17%). Some series found that PD-L1 positivity was associated with decreased time to castration resistance. Treatment with ipilimumab, cyclophosphamide/GVAX/degarelix, or degarelix alone may increase PD-L1 expression. Correlation of PD-L1 positivity with overall survival and outcomes related to tumor recurrence were rarely investigated; the few analyzed series produced conflicting results and sometimes showed limitations. Further studies are required. The testing and scoring of PD-L1 should be standardized.

What do we have to know about pd-l1 expression in prostate cancer? A systematic literature review. part 2: Clinic–pathologic correlations / Palicelli, A.; Bonacini, M.; Croci, S.; Magi-Galluzzi, C.; Canete-Portillo, S.; Chaux, A.; Bisagni, A.; Zanetti, E.; De Biase, D.; Melli, B.; Sanguedolce, F.; Zanelli, M.; Bonasoni, M. P.; De Marco, L.; Soriano, A.; Ascani, S.; Zizzo, M.; Ruiz, C. C.; De Leo, A.; Giordano, G.; Landriscina, M.; Carrieri, G.; Cormio, L.; Berney, D. M.; Gandhi, J.; Santandrea, G.; Gelli, M. C.; Tafuni, A.; Ragazzi, M.. - In: CELLS. - ISSN 2073-4409. - 10:11(2021), pp. 3165-3187. [10.3390/cells10113165]

What do we have to know about pd-l1 expression in prostate cancer? A systematic literature review. part 2: Clinic–pathologic correlations

Melli B.;Zanelli M.;Zizzo M.;De Leo A.;Giordano G.;Landriscina M.;Santandrea G.;Ragazzi M.
2021

Abstract

Many studies have investigated the potential prognostic and predictive role of PD-L1 in prostatic carcinoma (PC). We performed a systematic literature review (PRISMA guidelines) to critically evaluate human tissue-based studies (immunohistochemistry, molecular analysis, etc.), experimental research (cell lines, mouse models), and clinical trials. Despite some controversial results and study limitations, PD-L1 expression by tumor cells may be related to clinic–pathologic features of adverse outcome, including advanced tumor stage (high pT, presence of lymph node, and distant metastases), positivity of surgical margins, high Grade Group, and castration resistance. Different PD-L1 positivity rates may be observed in matched primary PCs and various metastatic sites of the same patients. Over-fixation, type/duration of decalcification, and PD-L1 antibody clone may influence the immunohistochemical analysis of PD-L1 on bone metastases. PD-L1 seemed expressed more frequently by castration-resistant PCs (49%) as compared to hormone-sensitive PCs (17%). Some series found that PD-L1 positivity was associated with decreased time to castration resistance. Treatment with ipilimumab, cyclophosphamide/GVAX/degarelix, or degarelix alone may increase PD-L1 expression. Correlation of PD-L1 positivity with overall survival and outcomes related to tumor recurrence were rarely investigated; the few analyzed series produced conflicting results and sometimes showed limitations. Further studies are required. The testing and scoring of PD-L1 should be standardized.
2021
10
11
3165
3187
What do we have to know about pd-l1 expression in prostate cancer? A systematic literature review. part 2: Clinic–pathologic correlations / Palicelli, A.; Bonacini, M.; Croci, S.; Magi-Galluzzi, C.; Canete-Portillo, S.; Chaux, A.; Bisagni, A.; Zanetti, E.; De Biase, D.; Melli, B.; Sanguedolce, F.; Zanelli, M.; Bonasoni, M. P.; De Marco, L.; Soriano, A.; Ascani, S.; Zizzo, M.; Ruiz, C. C.; De Leo, A.; Giordano, G.; Landriscina, M.; Carrieri, G.; Cormio, L.; Berney, D. M.; Gandhi, J.; Santandrea, G.; Gelli, M. C.; Tafuni, A.; Ragazzi, M.. - In: CELLS. - ISSN 2073-4409. - 10:11(2021), pp. 3165-3187. [10.3390/cells10113165]
Palicelli, A.; Bonacini, M.; Croci, S.; Magi-Galluzzi, C.; Canete-Portillo, S.; Chaux, A.; Bisagni, A.; Zanetti, E.; De Biase, D.; Melli, B.; Sanguedo...espandi
File in questo prodotto:
File Dimensione Formato  
PDL1 part 2_Cells 2021.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 564.34 kB
Formato Adobe PDF
564.34 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1302586
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 11
social impact